Vnitr Lek 2024, 70(3):166-172 | DOI: 10.36290/vnl.2024.034

Biological and innovative therapies of inflammatory bowel disease

Petra Mináriková
Interní klinika 1. LF UK a ÚVN Praha

Crohn's disease and ulcerative colitis are chronic, inflammatory bowel disease medically and surgically incurable. In the last 20 years, there has been a dramatic development, especially of medicamentous treatment. In biological therapy, new agents have been introduced with a mechanism of action targeted on molecules of key role in the pathogenesis of inflammatory bowel disease.

Keywords: inflammatory bowel disease, Crohn's disease, ulcerative colitis, drug treatment, biologics, small molecules.

Accepted: April 26, 2024; Published: May 6, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mináriková P. Biological and innovative therapies of inflammatory bowel disease. Vnitr Lek. 2024;70(3):166-172. doi: 10.36290/vnl.2024.034.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ahluwalia B, et al. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol. 2018;53(4):379-389. Go to original source... Go to PubMed...
    2. Lukáš M, et al. Idiopatické střevní záněty nové trendy a mezioborové souvislosti. 2020; ISBN 978-80-271-1208-1.
    3. Mináriková P. Současné možnosti medikamentózní léčby idiopatických střevních zánětů. Medicína po promoci. 2019;20(3):201-209.
    4. Bortlík M, Ďuricová D, Douda T, et al. Doporučení pro podávání biologické léčby pacientům s idiopatickými střevními záněty: čtvrté, aktualizované vydání. Gastroent Hepatol. 2019;73(1):11-24. Go to original source...
    5. Podolsky DK, et al. Yamada's textbook of Gastroenterology. 2016; ISBN 9781118512067. Go to original source...
    6. Zbořil V, et al. Idiopatické střevní záněty 2018; ISBN 978-80-204-4720-3
    7. Lukáš M, et al. Pokroky v diagnostice a léčbě idiopatických střevních zánětů. 2019; ISBN 978-80-7492-453-8.
    8. Peyrin-Biroulet L, Sandborn WJ, Sands BE, et al. Selecting therapeutic goals for treat to target. Am J Gastroenterol. 2015 Sep;110(9):1324-38. Go to original source... Go to PubMed...
    9. Strik AS, et al. Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward? Exp. Review of Clin Pharmacol. 2019;9:885-891. Go to original source... Go to PubMed...
    10. Papamichael K, Vajravelu RK, Vaughn BP, et al. Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. J Crohn's Colitis. 2018;28:12-17. Go to original source...
    11. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn's disease (CALM): a multientre randomized, controlled phase 3 trial. Lancet; 2018 Dec 23;390:10114. Go to original source... Go to PubMed...
    12. Ungaro I, et al. Deep remission at 1 year prevents progression of Early Crohn's Disease. Gastroenterology. 2020 July;159(1):139-147. Go to original source... Go to PubMed...
    13. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15):1383-1395. Go to original source... Go to PubMed...
    14. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392-400. Go to original source... Go to PubMed...
    15. Feldman SR, Bagel J, Namak S. Biosimilars for Immune-Mediated Chronic Disease in Primary Care: What a practicing physician needs to know. Am J Med Sci. 2018;355(5):411-417.Další literatura u autorky a na www.casopisvnitrnilekarstvi.cz Go to original source... Go to PubMed...
    16. Danese S, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease- an update. J Crohn's Colitis. 2017;26-34. Go to original source... Go to PubMed...
    17. Yoo DH Hrycaj P Mirand P, et al. A randomised, double-blind, multicentre, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann rheum Dis. 2013;72:1613-1620. Go to original source... Go to PubMed...
    18. Park W Hrycaj P Jeka S, et al. A randomized, double- blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605-1612. Go to original source... Go to PubMed...
    19. Schreiber S, et al. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology. 2021. Jun;160(7):2340-2353. Go to original source... Go to PubMed...
    20. Schreiber S, Ben-Horin S, Ye BD, et al. Development of novel auto-injector of subcutaneous CT-P13infliximab: Phase I randomized, open-label, single-dose trial to compare the pharmacokinetics and safety to pre-filled syringe in healthy subjects. J Crohn's Colitis. 2019;12(1):458-459. Go to original source...
    21. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2013;369: 699-710. Go to original source... Go to PubMed...
    22. Vermier S, D'Haens G, Baert F, et al. Efficacy and Safety of Subcutaneous Vedolizumab in Patients with Moderately to severely Active Crohn's Disease: Results from Visible 2 Randomised Trial. J Crohn's Colitis. 2022;16:27-38. Go to original source... Go to PubMed...
    23. Danese S, Colombel JF, Lukas M, et al on behalf of GARDENIA Study Group. Lancet Gastroenterol Hepatol. 2022;7:118-127.
    24. Sandborn WJ, Panese J, Danese S, et al. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomized, placebo-controlled, double-blind, phase3 trial. Lancet Gastroenterol Hepatol. 2023;8:43-55. Go to original source... Go to PubMed...
    25. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and maitenance Therapy for Crohn's Disease. N Engl J Med. 2016;375:1046-1960. Go to original source... Go to PubMed...
    26. Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019;381:1201-1214. Go to original source... Go to PubMed...
    27. D'Haens G, Panaccione R, Baert F, et al. Risankizuimab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trial. Lancet. 2022;399:2015-2030. Go to original source... Go to PubMed...
    28. D'Haens G, Dubinsky M, Kobayashi T, et al Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388:2444-55. Go to original source... Go to PubMed...
    29. Sandborn WJ, D'Haens GR, Reinisch W, et al. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 Galaxi-1 Study. Gastroenterology. 2022 May;162(6):1650-1664. Go to original source... Go to PubMed...
    30. Danese S, Argollo M, Le Berre C, Peyrin-Biroulet L. Jak selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut. 2019; 68(10):1893-1899. Go to original source... Go to PubMed...
    31. Rubin DT, Dubinski M, Lukas M, et al. Long-term efficacy of tofacitinib in patients who received extended induction therapy: results froom OCTAVE open study for tofacitinib delayed responders. J Crohn's Colitis. 2019;13(suppl 1):S050-S052. Go to original source...
    32. Sandborn WJ, Su C, Sands BE et al Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723-1736. Go to original source... Go to PubMed...
    33. Feagan B, Danese S, Loftus EV, et al. Filgotinib as Induction and maintenance Therapy for Ulcerative Colitis (SELECTION): A Phase 2 b/3 Double-Blind, randomisedd, Placebo- Controlled Trial Lancet. 2021;397:2372-2384. Go to original source... Go to PubMed...
    34. Reinisch W, Colombel JF, D'Haens GR, et al. Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulizing Crohn's Disease (DIVERGENCE 2): a Phase 2, Randomized, Placebo-Controlled Trial. J Crohn's Colitis. 2024 Feb. 16;XX:1-11. Go to original source... Go to PubMed...
    35. Danese S, Vermeire S, Zhou W, et al. Upadacitinib as Induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomized trials. Lancet. 2022 Jun 4; 39 (10341):2113-2128. Go to original source... Go to PubMed...
    36. Loftus EV Jr, Panes J, Lacerda AP, et al. Upadacitinib Induction and Maintenance therapy for Crohn's Disease N Engl J Med. 2023;388:1966-80. Go to original source... Go to PubMed...
    37. Sandborn WJ, Feagan BG, D'Haens G, et al. Ozanimod as Induction and maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021;385(14):1280-91. Go to original source... Go to PubMed...
    38. Ahmed W, Galati J, Kumar A, et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systemic review and meta-analysis Clin Gastroenterol Hepatol. 2022;20:e361-79. Go to original source... Go to PubMed...
    39. Mas EB, Calvo XC Selecting the best combined biological therapy for refraktory inflammatory bowel disease patients. J Clin Med. 2022;11:1076. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.